Can reactogenicity predict immunogenicity after COVID-19 vaccination?

Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods Adverse events were prospectively evaluated using an electronic diary in 135 healthy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Young Hoon Hwang, Kyoung-Ho Song, Yunsang Choi, Suryeong Go, Su-Jin Choi, Jongtak Jung, Chang Kyung Kang, Pyoeng Gyun Choe, Nam-Joong Kim, Wan Beom Park, Myoung-don Oh
Formato: article
Lenguaje:EN
Publicado: The Korean Association of Internal Medicine 2021
Materias:
R
Acceso en línea:https://doaj.org/article/a2c025690e8c4d0091640442ad05d2e9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a2c025690e8c4d0091640442ad05d2e9
record_format dspace
spelling oai:doaj.org-article:a2c025690e8c4d0091640442ad05d2e92021-11-08T00:59:06ZCan reactogenicity predict immunogenicity after COVID-19 vaccination?1226-33032005-664810.3904/kjim.2021.210https://doaj.org/article/a2c025690e8c4d0091640442ad05d2e92021-11-01T00:00:00Zhttp://www.kjim.org/upload/pdf/kjim-2021-210.pdfhttps://doaj.org/toc/1226-3303https://doaj.org/toc/2005-6648Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods Adverse events were prospectively evaluated using an electronic diary in 135 healthy adults who received a SARS-CoV-2 vaccine (AZD1222, AstraZeneca/Oxford, n = 42; or BNT162b2, Pfizer/BioNTech, n = 93). We semi-quantitatively measured anti-S1 immunoglobulin G (IgG) using an enzyme-linked immunosorbent assay at baseline, 3 weeks after the first dose of AZD1222 or BNT162b2, and 2 weeks after the second dose of BNT162b2. We evaluated the association between the maximum grade of local or systemic adverse events and the anti-S1 IgG optical density using multivariate linear regression with adjustment for age, sex, and use of antipyretics. Results The median age of the 135 vaccinees was 30 years (36 years in the AZD1222 group and 29 years in the BNT162b2 group) and 25.9% were male (9.5% in the AZD1222 group and 33.3% in the BNT162b2 group). Local and systemic adverse events were generally comparable after the first dose of AZD1222 and the second dose of BNT162b2. The grades of local and systemic adverse events were not significantly associated with anti-S1 IgG levels in the AZD1222 or BNT162b2 group. Conclusions Local and systemic reactogenicity may not be associated with humoral immunogenicity after SARS-CoV-2 vaccination.Young Hoon HwangKyoung-Ho SongYunsang ChoiSuryeong GoSu-Jin ChoiJongtak JungChang Kyung KangPyoeng Gyun ChoeNam-Joong KimWan Beom ParkMyoung-don OhThe Korean Association of Internal Medicinearticlecovid-19sars-cov-2immunogenicityvaccinedrug-related side effects and adverse reactionsenzyme-linked immunosorbent assayMedicineRENThe Korean Journal of Internal Medicine, Vol 36, Iss 6, Pp 1486-1491 (2021)
institution DOAJ
collection DOAJ
language EN
topic covid-19
sars-cov-2
immunogenicity
vaccine
drug-related side effects and adverse reactions
enzyme-linked immunosorbent assay
Medicine
R
spellingShingle covid-19
sars-cov-2
immunogenicity
vaccine
drug-related side effects and adverse reactions
enzyme-linked immunosorbent assay
Medicine
R
Young Hoon Hwang
Kyoung-Ho Song
Yunsang Choi
Suryeong Go
Su-Jin Choi
Jongtak Jung
Chang Kyung Kang
Pyoeng Gyun Choe
Nam-Joong Kim
Wan Beom Park
Myoung-don Oh
Can reactogenicity predict immunogenicity after COVID-19 vaccination?
description Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods Adverse events were prospectively evaluated using an electronic diary in 135 healthy adults who received a SARS-CoV-2 vaccine (AZD1222, AstraZeneca/Oxford, n = 42; or BNT162b2, Pfizer/BioNTech, n = 93). We semi-quantitatively measured anti-S1 immunoglobulin G (IgG) using an enzyme-linked immunosorbent assay at baseline, 3 weeks after the first dose of AZD1222 or BNT162b2, and 2 weeks after the second dose of BNT162b2. We evaluated the association between the maximum grade of local or systemic adverse events and the anti-S1 IgG optical density using multivariate linear regression with adjustment for age, sex, and use of antipyretics. Results The median age of the 135 vaccinees was 30 years (36 years in the AZD1222 group and 29 years in the BNT162b2 group) and 25.9% were male (9.5% in the AZD1222 group and 33.3% in the BNT162b2 group). Local and systemic adverse events were generally comparable after the first dose of AZD1222 and the second dose of BNT162b2. The grades of local and systemic adverse events were not significantly associated with anti-S1 IgG levels in the AZD1222 or BNT162b2 group. Conclusions Local and systemic reactogenicity may not be associated with humoral immunogenicity after SARS-CoV-2 vaccination.
format article
author Young Hoon Hwang
Kyoung-Ho Song
Yunsang Choi
Suryeong Go
Su-Jin Choi
Jongtak Jung
Chang Kyung Kang
Pyoeng Gyun Choe
Nam-Joong Kim
Wan Beom Park
Myoung-don Oh
author_facet Young Hoon Hwang
Kyoung-Ho Song
Yunsang Choi
Suryeong Go
Su-Jin Choi
Jongtak Jung
Chang Kyung Kang
Pyoeng Gyun Choe
Nam-Joong Kim
Wan Beom Park
Myoung-don Oh
author_sort Young Hoon Hwang
title Can reactogenicity predict immunogenicity after COVID-19 vaccination?
title_short Can reactogenicity predict immunogenicity after COVID-19 vaccination?
title_full Can reactogenicity predict immunogenicity after COVID-19 vaccination?
title_fullStr Can reactogenicity predict immunogenicity after COVID-19 vaccination?
title_full_unstemmed Can reactogenicity predict immunogenicity after COVID-19 vaccination?
title_sort can reactogenicity predict immunogenicity after covid-19 vaccination?
publisher The Korean Association of Internal Medicine
publishDate 2021
url https://doaj.org/article/a2c025690e8c4d0091640442ad05d2e9
work_keys_str_mv AT younghoonhwang canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT kyounghosong canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT yunsangchoi canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT suryeonggo canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT sujinchoi canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT jongtakjung canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT changkyungkang canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT pyoenggyunchoe canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT namjoongkim canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT wanbeompark canreactogenicitypredictimmunogenicityaftercovid19vaccination
AT myoungdonoh canreactogenicitypredictimmunogenicityaftercovid19vaccination
_version_ 1718443302730072064